Background: This study explores the epidemiology, treatment and outcomes of hepatocellular carcinoma (HCC) in a sub-Saharan cohort, comparing patients with and without human immunodeficiency virus (HIV).
Methods: A retrospective cohort study of patients treated for HCC from 1 February 2011 to 29 February 2024 at Groote Schuur Hospital, South Africa was performed.
Results: Of the 501 HCC patients, 75 (15.0 %) were people living with HIV (PLWH). The PLWH were younger (43.7 ± 9.7 vs. 52.9 ± 15.3 years, p < 0.00001), had more frequent chronic hepatitis B virus (HBV) co-infection (85.3 % vs. 51.6 %, p < 0.00001) and no hepatitis C virus co-infection (0 % vs. 6.8 %, p = 0.013). More PLWH presented with Barcelona Clinic Liver Cancer Stage D disease (43.6 % vs. 27.7 %, p = 0.007). Similar proportions of PLWH and HIV-negative patients received curative-intended treatments, life-prolonging therapies and best supportive care. In PLWH, the median survival was lower (44 [IQR: 16-163.7] vs. 78 [IQR: 26-191] days, p = 0.010), and patients with HIV-HBV co-infection had the lowest survival (39 [IQR: 14.7-155.2] days).
Conclusion: In a sub-Saharan HCC cohort, patients with HIV were significantly younger, had more advanced disease and HBV co-infection resulted in the lowest survival. Earlier detection through aggressive HCC screening is key to improving outcomes in PLWH.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.hpb.2025.02.012 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comprehensive systems biology analysis of microRNA-101-3p regulatory network identifies crucial genes and pathways in hepatocellular carcinoma.
J Genet Eng Biotechnol
March 2025
Department of Pharmacognosy and Pharmaceutical Biotechnology, School of Pharmacy, Iran University of Medical Sciences, Tehran, Iran.
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide. This study aimed to explore the role of hsa-miR-101-3p in HCC pathogenesis by identifying key genes and pathways. A comprehensive bioinformatics analysis revealed twelve hub genes (ETNK1, BICRA, IL1R1, KDM3A, ARID2, GSK3β, EZH2, NOTCH1, SMARCA4, FOS, CREB1, and CASP3) and highlighted their involvement in crucial oncogenic pathways, including PI3K/Akt, mTOR, MAPK, and TGF-β.
View Article and Find Full Text PDFIntroduction: Systematic therapies, including tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs), have now been approved as the mainstay treatment for patients with unresectable hepatocellular carcinoma (uHCC). However, only a minority of the patients are expected to respond to TKIs and ICIs. Because early tumor shrinkage (ETS) and depth of response (DoR) might have the potential to predict survival outcomes, this study aimed to identify the optimal cutoffs for ETS and DoR to predict patients' clinical outcomes in their early treatment stage.
View Article and Find Full Text PDFImmo-bile-izing CD8 T cell anti-tumor immunity.
Immunity
March 2025
Blacktown Clinical School, Western Sydney University, Sydney, NSW 2148, Australia; Storr Liver Centre, Westmead Institute for Medical Research, Sydney, NSW 2145, Australia; Blacktown Mt Druitt Hospital, Sydney, NSW 2148, Australia. Electronic address:
Hepatocellular carcinoma is poorly responsive to immune checkpoint blockade. In a recent issue of Science, Varanasi et al. reveal how bile acids dampen anti-tumor CD8 T cell responses in the liver, contributing to cancer progression and poor immunotherapy outcomes.
View Article and Find Full Text PDFAssociation Between Mortality and Detection of Respiratory Viruses in Children During the Peri-Liver Transplant Period.
Pediatr Infect Dis J
March 2025
Department of Pediatrics and Intensive Care Medicine.
Background: To evaluate the disease burden, risk of complications and mortality in children with viral detection during the peri-liver transplant period.
Methods: A retrospective cohort study was conducted between January 2020 and December 2023 at a tertiary university hospital. Children who underwent multiplex polymerase chain reaction testing from 7 days before to 14 days after liver transplantation were included.
Synthetic Versus Biologic Mesh for Complex Open Ventral Hernia Repair: 3-Year Follow-Up of a Pilot Randomized Controlled Trial.
HCA Healthc J Med
February 2025
University of Houston, HCA Kingwood, Kingwood, Texas.
Background: Biologic mesh is often used in complex hernia repair, but there has been limited clinical evidence to date to support this practice. The aim of this study was to compare clinical and patient-reported outcomes of biologic versus synthetic mesh for complex open ventral hernia repair (OVHR) at 3 years.
Methods: Patients from a single center, randomized, controlled, pilot trial comparing biologic versus synthetic mesh in complex OVHR were followed for 3 years.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!